Passage Bio Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Passage Bio stock.
View analyst ratings for Passage Bio or view top-rated stocks.

Wall Street analysts have given Passage Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Passage Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Passage Bio is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Passage Bio.

Passage Bio, Inc. (NASDAQ:PASG) posted its quarterly earnings data on Tuesday, March, 2nd. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by $0.14.
View Passage Bio's earnings history.

Passage Bio's stock was trading at $18.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PASG shares have increased by 5.1% and is now trading at $19.83.
View which stocks have been most impacted by COVID-19.

8 brokerages have issued 12 month price objectives for Passage Bio's stock. Their forecasts range from $2.21 to $35.00. On average, they expect Passage Bio's stock price to reach $25.53 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price.
View analysts' price targets for Passage Bio or view top-rated stocks among Wall Street analysts.

Some companies that are related to Passage Bio include Relay Therapeutics (RLAY), Revolution Medicines (RVMD), NantKwest (NK), Editas Medicine (EDIT), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), Kymera Therapeutics (KYMR), Bavarian Nordic A/S (BVNRY), AlloVir (ALVR), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), bluebird bio (BLUE), Scholar Rock (SRRK), C4 Therapeutics (CCCC) and Translate Bio (TBIO).
View all of PASG's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX), Gossamer Bio (GOSS), JD.com (JD), Micron Technology (MU) and Black Diamond Therapeutics (BDTX).

(PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Chardan was co-manager.

Passage Bio trades on the NASDAQ under the ticker symbol "PASG."

Passage Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.82%), Highline Capital Management L.P. (1.31%), Morgan Stanley (0.92%), Emerald Advisers LLC (0.74%), Alyeska Investment Group L.P. (0.63%) and Alyeska Investment Group L.P. (0.63%). Company insiders that own Passage Bio stock include Alexandros Fotopoulos, Athena Countouriotis, Bruce A Goldsmith, Jill M Quigley, Life Sciences Ix LP Frazier and Thomas Woiwode.
View institutional ownership trends for Passage Bio.

PASG stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Baker BROS. Advisors LP, Swiss National Bank, Squarepoint Ops LLC, State of Wisconsin Investment Board, Alyeska Investment Group L.P., Alyeska Investment Group L.P., and Emerald Advisers LLC.
View insider buying and selling activity for Passage Bio or view top insider-selling stocks.

PASG stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Ikarian Capital LLC, Northern Trust Corp, Victory Capital Management Inc., Norges Bank, Charles Schwab Investment Management Inc., and Bank of New York Mellon Corp. Company insiders that have bought Passage Bio stock in the last two years include Alexandros Fotopoulos, Athena Countouriotis, Bruce A Goldsmith, Jill M Quigley, Life Sciences Ix LP Frazier, and Thomas Woiwode.
View insider buying and selling activity for Passage Bio or or view top insider-buying stocks.

Shares of PASG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PASG stock can currently be purchased for approximately $19.83.

Passage Bio has a market capitalization of $910.53 million.

Passage Bio employs 20 workers across the globe.

The official website for Passage Bio is www.passagebio.com.

Passage Bio is headquartered at TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103.

Passage Bio's mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The company can be reached via phone at 267-866-0311 or via email at [email protected]